Date: 2015-06-24
Type of information: Grant
Company: Moberg Pharma (Sweden)
Investors: European Eurostars Programme (EU)
Amount: € 0.9 million
Funding type: grant
Planned used: The funding from Eurostars will be used to support Moberg Pharma’s BUPI project. It will co-finance late-stage development of the product including a clinical phase III study. The BUPI technology encompasses novel lozenge formulations of bupivacaine, a local anesthetic with a well-established long acting effect, currently available on the market for other indications as an injectable. A BUPI lozenge is currently investigated in an ongoing clinical phase II study. The Eurostars project “BUPI - a long-acting lozenge with bupivacaine for pain relief of Oral Mucositis in cancer patients” will be managed by Moberg Pharma and includes six external partners in Sweden and Denmark: Oracain, TFS Trial Form Support ApS, Aarhus University Hospital, University Hospital Herlev, PCG Clinical Services and Skåne University Hospital.
Others: * On June 24, 2015, Moberg Pharma announced that a grant of € 0.9 million in public funding has been approved by Eurostars for a project proposal related to late-stage development of Moberg Pharma’s BUPI project.
The Eurostars project “BUPI - a long-acting lozenge with bupivacaine for pain relief of Oral Mucositis in cancer patients” will be managed by Moberg Pharma and includes six external partners in Sweden and Denmark: Oracain, TFS Trial Form Support ApS, Aarhus University Hospital, University Hospital Herlev, PCG Clinical Services and Skåne University Hospital.
Therapeutic area: Infectious diseases
